US FDA Accepts Genmab's A/S IND for HuMax-CD20 to Treat Active Rheumatoid Arthritis
A total of 60 patients will be randomized into three cohorts each containing 20 patients. In each cohort 16 patients will receive two infusions of HuMax-CD20 (300, 700 or 1000 mg doses) and 4 patients will receive placebo given 14 days apart. All patients in the study will also receive methotrexate, a recognized treatment in the US for RA. Patients will be followed for 24 weeks to evaluate safety and efficacy and then every 12 weeks until B-cell counts return to baseline levels. Genmab plans to initiate the study during the early part of 2005.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.